Cited by 196Dementia and Cognitive Impairment ResearchAlzheimer's disease research and treatmentsCancer-related cognitive impairment studies

The DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.

Association of Elevated Amyloid Levels With Cognition and Biomarkers in Cognitively Normal People From the Community

Open access

Petersen, Ronald C., Wiste, Heather J., Weigand, Stephen D., Rocca, Walter A., Roberts, Rosebud O., Mielke, Michelle M., Lowe, Val J., Knopman, David S., Pankratz, Vernon S., Machulda, Mary M., Geda, Yonas E., Jack, Clifford R.·2016·JAMA Neurology

DOI 10.1001/jamaneurol.2015.3098PMC PMC4710552

Open this paper in CoChat — free account

Abstract

IMPORTANCE: The role of amyloid in the progression of Alzheimer disease (AD) pathophysiology is of central interest to the design of randomized clinical trials. The presence of amyloid has become a prerequisite for enrollment in several secondary prevention trials for AD, yet the precise effect of elevated amyloid levels on subsequent clinical and biomarker events is less certain. OBJECTIVE: To explore the effect of elevated amyloid levels on subsequent changes in cognition and biomarkers. DESIGN, SETTING, AND PARTICIPANTS: A total of 564 cognitively normal individuals (median age, 78 years) from the Mayo Clinic Study of Aging, a population-based longitudinal study in Olmsted County, Minnesota, with serial cognitive data were selected for this study. The data used in this study were collected from January 12, 2006, to January 9, 2014. Individuals included in this study had undergone magnetic resonance imaging, fluorodeoxyglucose positron emission tomography (FDG-PET), and Pittsburgh Compound B (PiB) PET at baseline were not cognitively impaired at baseline and had at least 1 clinical follow-up. A subset of 286 individuals also underwent serial imaging. Elevated amyloid level was defined as a standardized uptake value ratio of greater than 1.5 on PiB PET. Associations with baseline amyloid status and baseline and longitudinal change in clinical and imaging measures were evaluated after adjusting for age and hippocampal volume. APOE4 effects were also evaluated. MAIN OUTCOMES AND MEASURES: Cognitive measures of memory, language, attention/executive function, visuospatial skills, PiB levels, hippocampal and ventricular volumes, and FDG-PET measures. RESULTS: At baseline, 179 (31.7%) individuals with elevated amyloid levels had poorer cognition in all domains measured, reduced hippocampal volume, and greater FDG-PET hypometabolism. Elevated amyloid levels at baseline were associated with a greater rate of cognitive decline in all domains (0.04 to 0.09 z score units per year) except language and a greater rate of amyloid accumulation (1.6% per year), hippocampal atrophy (30 mm3 per year), and ventricular enlargement (565 mm3 per year). Elevated amyloid levels were also associated with an increased risk of mild cognitive impairment (hazard ratio, 2.9; 95% CI, 1.7-5.0, and hazard ratio, 1.6; 95% CI, 0.9-2.8, for PiB+ APOE4 carriers and PiB+ noncarriers, respectively, compared with PiB- noncarriers). These associations were largely independent of APOE4. CONCLUSIONS AND RELEVANCE: In persons selected from a population-based study, elevated amyloid levels at baseline were associated with worse cognition and imaging biomarkers at baseline and with greater clinical decline and neurodegeneration. These results have implications for the design of randomized clinical trials for AD.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1001/jamaneurol.2015.3098

Cites

36 of 36 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

The diagnosis of dementia due to Alzheimer's disease: Recommendations from the National Institute on Aging‐Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease
McKhann, G. M., Knopman, D. S., Chertkow, H., Hyman, B. T., Jack, C. R., Kawas, C. H., Klunk, W. E., Koroshetz, W. J., Manly, J. J., Mayeux, R., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.005 · Cited by 18,657
Self-citation
The diagnosis of mild cognitive impairment due to Alzheimer's disease: Recommendations from the National Institute on Aging‐Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease
Albert, M. S., DeKosky, S. T., Dickson, D., Dubois, B., Feldman, H. H., Fox, N. C., Gamst, A., Holtzman, D. M., Jagust, W. J., Petersen, R. C., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.008 · Cited by 10,152
Self-citation
The Clinical Dementia Rating (CDR): Current version and scoring rules
Morris, J. C. (1993) · Neurology · doi:10.1212/wnl.43.11.2412-a · Cited by 9,882
Mild cognitive impairment as a diagnostic entity
Petersen, R. C. (2004) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2004.01388.x · Cited by 7,864
Self-citation
Toward defining the preclinical stages of Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease
Sperling, R. A., Aisen, P. S., Beckett, L. A., Bennett, D. A., Craft, S., Fagan, A. M., Iwatsubo, T., Jack, C. R., Kaye, J., Montine, T. J., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.003 · Cited by 7,155
Self-citation
Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers
Jack, C. R., Knopman, D. S., Jagust, W. J., Petersen, R. C., Weiner, M. W., Aisen, P. S., Shaw, L. M., Vemuri, P., Wiste, H. J., Weigand, S. D., et al. (2013) · The Lancet Neurology · doi:10.1016/s1474-4422(12)70291-0 · Cited by 4,396
Self-citation
The Diagnosis of Mild Cognitive Impairment due to Alzheimer’s Disease: Recommendations from the National Institute on Aging-Alzheimer’s Association Workgroups on Diagnostic Guidelines for Alzheimer’s Disease
Albert, M., DeKosky, S. T., Dickson, D. W., Dubois, B., Feldman, H., Fox, N. C., Gamst, A. C., Holtzman, D. M., Jagust, W. J., Petersen, R. C., et al. (2013) · FOCUS The Journal of Lifelong Learning in Psychiatry · doi:10.1176/appi.focus.11.1.96 · Cited by 2,643
Self-citation
Amyloid β deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer's disease: a prospective cohort study
Villemagne, V. L., Burnham, S., Bourgeat, P., Brown, B., Ellis, K. A., Salvado, O., Szoeke, C., Macaulay, S. L., Martins, R., Maruff, P., et al. (2013) · The Lancet Neurology · doi:10.1016/s1474-4422(13)70044-9 · Cited by 2,279
Serial PIB and MRI in normal, mild cognitive impairment and Alzheimer's disease: implications for sequence of pathological events in Alzheimer's disease
Jack, C. R., Lowe, V. J., Weigand, S. D., Wiste, H. J., Senjem, M. L., Knopman, D. S., Shiung, M. M., Gunter, J. L., Boeve, B. F., Kemp, B. J., et al. (2009) · Brain · doi:10.1093/brain/awp062 · Cited by 1,099
Self-citation
Biomarker Modeling of Alzheimer’s Disease
Jack, C. R., & Holtzman, D. M. (2013) · Neuron · doi:10.1016/j.neuron.2013.12.003 · Cited by 1,002
Self-citation

Flagged first, then by citations

Show all 36 references

Research works printed but not linked: 1

[33]Jack CR Jr Knopman DS Weigand SD An operational approach to NIA-AA crtiteria for preclinical Alzheimer’s disease Ann Neurol 2012 71 6 765 775 22488240 PMC3586223

Sorted by citations

Items 101–196 of 196

Visual paired associate learning deficits associated with elevated beta-amyloid in cognitively normal older adults.
Baker, J. E., Pietrzak, R. H., Laws, S. M., Ames, D. J., Villemagne, V. L., Rowe, C. C., Masters, C. L., Maruff, P. T., & Lim, Y. Y. (2019) · Neuropsychology · doi:10.1037/neu0000561 · Cited by 22
Future Directions in Imaging Neurodegeneration
Masdeu, J. C. (2017) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-017-0718-1 · Cited by 22
High Glycemic Diet Is Related to Brain Amyloid Accumulation Over One Year in Preclinical Alzheimer's Disease
Taylor, M., Sullivan, D. K., Morris, J. K., Vidoni, E. D., Honea, R. A., Mahnken, J. D., & Burns, J. M. (2021) · Frontiers in Nutrition · doi:10.3389/fnut.2021.741534 · Cited by 28
Posterior cingulate cortex reveals an expression profile of resilience in cognitively intact elders
Kelley, C. M., Ginsberg, S. D., Liang, W. S., Counts, S., & Mufson, E. J. (2022) · Brain Communications · doi:10.1093/braincomms/fcac162 · Cited by 23
Performance on the Cogstate Brief Battery Is Related to Amyloid Levels and Hippocampal Volume in Very Mild Dementia
Lim, Y. Y., Villemagne, V. L., Laws, S. M., Pietrzak, R. H., Ames, D. J., Fowler, C. J., Rainey‐Smith, S. R., Snyder, P. J., Bourgeat, P., Martins, R. N., et al. (2016) · Journal of Molecular Neuroscience · doi:10.1007/s12031-016-0822-8 · Cited by 21
The effect of amyloid deposition on longitudinal resting-state functional connectivity in cognitively normal older adults
Lin, C., Ly, M., Karim, H. T., Wei, W., Snitz, B. E., Klunk, W. E., & Aizenstein, H. J. (2020) · Alzheimer's Research & Therapy · doi:10.1186/s13195-019-0573-1 · Cited by 19
Prospective Associations between Plasma Amyloid-Beta 42/40 and Frailty in Community-Dwelling Older Adults
Lu, W., Giudici, K. V., Rolland, Y., Guyonnet, S., Li, Y., Bateman, R. J., Barreto, P. D. S., & Vellas, B. J. (2021) · The Journal of Prevention of Alzheimer s Disease · doi:10.14283/jpad.2020.60 · Cited by 17
Biomarkers and Tools for Predicting Alzheimer's Disease in the Preclinical Stage
Li, T., Yang, Q. Z., Hu, X., & Han, Y. (2022) · Kölner Universitäts PublikationsServer (Universität zu Köln) · Cited by 17
Functional Network Alterations Associated with Cognition in Pre-Clinical Alzheimer's Disease
Fountain‐Zaragoza, S., Liu, H., & Benitez, A. M. (2023) · Brain Connectivity · doi:10.1089/brain.2022.0032 · Cited by 19
[18F]-D3FSP β-amyloid PET imaging in older adults and alzheimer’s disease
Li, A., Zhao, R., Zhang, M., Sun, P., Cai, Y. Q., Zhu, L., Kung, H. F., Han, Y., Wang, X., & Guo, T. (2024) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-024-06835-2 · Cited by 17
Amyloid‐β, cortical thickness, and subsequent cognitive decline in cognitively normal oldest‐old
Pelkmans, W., Legdeur, N., ten Kate, M., Barkhof, F., Yaqub, M. M., Holstege, H. H., van Berckel, B. N. M., Scheltens, P., van der Flier, W. M., Visser, P. J., et al. (2021) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.51273 · Cited by 17
Insomnia Moderates the Relationship Between Amyloid-β and Cognitive Decline in Late-Life Adults without Dementia
Xu, W., Initiative, A. D. N., Tan, C., Zou, J., Cao, X., & Tan, L. (2021) · Journal of Alzheimer s Disease · doi:10.3233/jad-201582 · Cited by 19
Are subjective cognitive complaints associated with executive functions and mental health of older adults?
Fastame, M. C. (2022) · Cognitive Processing · doi:10.1007/s10339-022-01089-y · Cited by 16
Cortical microstructural changes predict tau accumulation and episodic memory decline in older adults harboring amyloid
Gagliardi, G. P., Rodriguez‐Vieitez, E., Montal, V., Sepulcre, J., Diez, I. P., Lois, C., Hanseeuw, B. J., Schultz, A. P., Properzi, M. J., Papp, K. V., et al. (2023) · Communications Medicine · doi:10.1038/s43856-023-00324-7 · Cited by 16
Gray Matter Densities in Limbic Areas and APOE4 Independently Predict Cognitive Decline in Normal Brain Aging
Herrmann, F. R., Rodriguez, C. K., Haller, S., Garibotto, V., Montandon, M., & Giannakopoulos, P. (2019) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2019.00157 · Cited by 16
Evaluation of Blood-Based Plasma Biomarkers as Potential Markers of Amyloid Burden in Preclinical Alzheimer’s Disease
Winston, C. N., Langford, O., Levin, N., Raman, R., Yarasheski, K. E., West, T., Abdel‐Latif, S., Donohue, M., Nakamura, A., Toba, K., et al. (2023) · Journal of Alzheimer s Disease · doi:10.3233/jad-221118 · Cited by 16
Amyloid Load, Hippocampal Volume Loss, and Diffusion Tensor Imaging Changes in Early Phases of Brain Aging
Haller, S., Montandon, M., Rodriguez, C. K., Garibotto, V., Lilja, J., Herrmann, F. R., & Giannakopoulos, P. (2019) · Frontiers in Neuroscience · doi:10.3389/fnins.2019.01228 · Cited by 16
Early cerebral amyloid-β accumulation and hypermetabolism are associated with subtle cognitive deficits before accelerated cerebral atrophy
Bakhtiari, A., Benedek, K., Law, I. G., Fagerlund, B., Mortensen, E. L., Osler, M., Lauritzen, M., Larsson, H. B. W., & Vestergaard, M. B. (2023) · GeroScience · doi:10.1007/s11357-023-01031-w · Cited by 17
Neuroimaging of Diseases Causing Dementia
Masdeu, J. C. (2019) · Neurologic Clinics · doi:10.1016/j.ncl.2019.08.003 · Cited by 16
The preclinical amyloid sensitive composite to determine subtle cognitive differences in preclinical Alzheimer’s disease
Hahn, A., Kim, Y. J., Kim, H. J., Jang, H., Cho, H., Choi, S. H., Kim, B. C., Park, K. W., Na, D. L., Chin, J., et al. (2020) · Scientific Reports · doi:10.1038/s41598-020-70386-3 · Cited by 17
P-tau and neurodegeneration mediate the effect of β-amyloid on cognition in non-demented elders
Ma, L., Hu, H., Wang, Z.-T., Ou, Y., Dong, Q., Tan, L., & Yu, J. (2021) · Alzheimer s Research & Therapy · doi:10.1186/s13195-021-00943-z · Cited by 16
A Brief Review of Paradigm Shifts in Prevention of Alzheimer’s Disease: From Cognitive Reserve to Precision Medicine
Hahn, C., & Lee, C. U. (2019) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2019.00786 · Cited by 15
Brain Amyloid Pathology and Cognitive Function
Visser, P. J., & Tijms, B. M. (2017) · JAMA · doi:10.1001/jama.2017.6895 · Cited by 15
A Pragmatic, Investigator-Driven Process for Disclosure of Amyloid PET Scan Results to ADNI-4 Research Participants
Erickson, C. M., Karlawish, J. H., Grill, J. D., Harkins, K. A., Landau, S. M., Mindt, M. R., Okonkwo, O. C., Petersen, R. C., Aisen, P. S. S., Weiner, M. W., et al. (2024) · The Journal of Prevention of Alzheimer s Disease · doi:10.14283/jpad.2024.33 · Cited by 14
Self-citation
Plasma tau predicts cerebral vulnerability in aging
Cantero, J. L., Atienza, M., Ramos‐Cejudo, J., Fossati, S., Wısnıewskı, T., & Osorio, R. S. (2020) · Aging · doi:10.18632/aging.104057 · Cited by 13
Increased Glucose Activity in Subgenual Anterior Cingulate and Hippocampus of High Performing Older Adults, Despite Amyloid Burden
Borelli, W. V., Leal‐Conceição, E., Andrade, M. A., Esper, N. B., Feltes, P. K., Soder, R. B., Matushita, C. S., Hartmann, L. M., Radaelli, G., Schilling, L. P., et al. (2021) · Journal of Alzheimer s Disease · doi:10.3233/jad-210063 · Cited by 13
Smartphone- and Tablet-Based Tools to Assess Cognition in Individuals With Preclinical Alzheimer Disease and Mild Cognitive Impairment: Scoping Review
van den Berg, R. L., van der Landen, S. M., Keijzer, M. J., van Gils, A. M., van Dam, M., Ziesemer, K. A., Jutten, R. J., Harrison, J., de Boer, C., van der Flier, W. M., et al. (2025) · Journal of Medical Internet Research · doi:10.2196/65297 · Cited by 14
Normal Aging and Dementia
Prendecki, M., Florczak‐Wyspianska, J., Kowalska, M., Lianeri, M., Kozubski, W. P., & Dorszewska, J. (2016) · InTech eBooks · doi:10.5772/64203 · Cited by 12
Association of Alzheimer’s Disease Genetic Risk Loci with Cognitive Performance and Decline: A Systematic Review
Andrews, S. J., McFall, G. P., Booth, A., Dixon, R. A., & Anstey, K. J. (2019) · Journal of Alzheimer s Disease · doi:10.3233/jad-190342 · Cited by 13
Microbleeds and Medial Temporal Atrophy Determine Cognitive Trajectories in Normal Aging: A Longitudinal PET-MRI Study
Montandon, M., Herrmann, F. R., Garibotto, V., Rodriguez, C. K., Haller, S., & Giannakopoulos, P. (2020) · Journal of Alzheimer s Disease · doi:10.3233/jad-200559 · Cited by 12
Idea selection for propositional language production
Barker, M. S., Ceslis, A., & Robinson, G. A. (2020) · Aging Neuropsychology and Cognition · doi:10.1080/13825585.2020.1862044 · Cited by 13
Molecular Diagnostics of Ageing and Tackling Age-related Disease
Timmons, J. A. (2016) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2016.11.005 · Cited by 10
APOE ɛ4 Genotype, Amyloid, and Clinical Disease Progression in Cognitively Normal Older Adults
Hollands, S., Lim, Y. Y., Laws, S. M., Villemagne, V. L., Pietrzak, R. H., Harrington, K., Porter, T., Snyder, P. J., Ames, D. J., Fowler, C. J., et al. (2017) · Journal of Alzheimer s Disease · doi:10.3233/jad-161019 · Cited by 11
Associations of Amyloid Burden, White Matter Hyperintensities, and Hippocampal Volume With Cognitive Trajectories in the 90+ Study
Wang, J., Ackley, S. F., Woodworth, D. C., Sajjadi, S. A., DeCarli, C. S., Fletcher, E. M., Glymour, M. M., Jiang, L., Kawas, C. H., & Corrada, M. M. (2024) · Neurology · doi:10.1212/wnl.0000000000209665 · Cited by 10
In Vivo and In Vitro Characteristics of Radiolabeled Vesamicol Analogs as the Vesicular Acetylcholine Transporter Imaging Agents
Ogawa, K., & Shiba, K. (2018) · Contrast Media & Molecular Imaging · doi:10.1155/2018/4535476 · Cited by 11
Association Between Visual Memory andIn VivoAmyloid and Tau Pathology in Preclinical Autosomal Dominant Alzheimer’s Disease
Bocanegra, Y., Fox‐Fuller, J. T., Baena, A. Y., Guzmán‐Vélez, E., Vila‐Castelar, C., Martinez, J. E., Torrico‐Teave, H., Lopera, F. J., & Quiroz, Y. T. (2020) · Journal of the International Neuropsychological Society · doi:10.1017/s1355617720000673 · Cited by 10
Preclinical Alzheimer’s Disease: Implications for Refinement of the Concept
Vos, S. J. B., & Visser, P. J. (2018) · Journal of Alzheimer s Disease · doi:10.3233/jad-179943 · Cited by 12
Associations Between the Subjective Cognitive Decline-Questionnaire’s Scores, Gray Matter Volume, and Amyloid-β Levels
Valech, N., Sánchez‐Benavides, G., Tort‐Merino, A., Coll‐Padrós, N., Olives, J., León, M., Falcón, C., Molinuevo, J. L., & Rami, L. (2019) · Journal of Alzheimer s Disease · doi:10.3233/jad-190624 · Cited by 9
Latent change‐on‐change between amyloid accumulation and cognitive decline
Klinger, H. M., Healy, B. C., Hanseeuw, B. J., Jones, R. N., Boyle, R. T., Townsend, D. L., Properzi, M. J., Coughlan, G., Seto, M., Birkenbihl, C., et al. (2024) · Alzheimer s & Dementia · doi:10.1002/alz.14326 · Cited by 6
Pathological correlates of impaired self-awareness of memory function in Alzheimer’s disease
Gagliardi, G. P., Kuppe, M. K., Lois, C., Hanseeuw, B. J., Vannini, P., & Initiative, A. D. N. (2021) · Alzheimer s Research & Therapy · doi:10.1186/s13195-021-00856-x · Cited by 8
Relationship Between PET-Assessed Amyloid Burden and Visual and Verbal Episodic Memory Performance in Elderly Subjects
Squarzoni, P., Faria, D. D. P., Yassuda, M. S., Porto, F. H. D. G., Coutinho, A. M., da Costa, N. A., Nitríni, R., Forlenza, O. V., Duran, F., Brucki, S. M. D., et al. (2020) · Journal of Alzheimer s Disease · doi:10.3233/jad-200758 · Cited by 8
Cortico-limbic volume abnormalities in late life depression are distinct from β amyloid and white matter pathologies
Mackin, R. S., Rhodes, E., Kassel, M. T., Kryza‐Lacombe, M., Burns, E., Bickford, D. D., Morin, R. T., Tosun, D., Landau, S. M., Butters, M. A., et al. (2024) · Molecular Psychiatry · doi:10.1038/s41380-024-02677-4 · Cited by 8
Self-citation
Oral Immunization with Soybean Storage Protein Containing Amyloid-β 4–10 Prevents Spatial Learning Decline
Kawarabayashi, T., Terakawa, T., Takahashi, A., Hasegawa, H., Narita, S., Sato, K., Nakamura, T., Seino, Y., Hirohata, M., Baba, N., et al. (2019) · Journal of Alzheimer s Disease · doi:10.3233/jad-190023 · Cited by 6
Amyloid deposition and small vessel disease are associated with cognitive function in older adults with type 2 diabetes
Lesman‐Segev, O. H., Golan, S., Ravona‐Springer, R., Livny, A., Lin, H., Ouyang, Y., Zadok, M., Ganmore, I., Heymann, A. D., Hoffmann, C., et al. (2024) · Scientific Reports · doi:10.1038/s41598-024-53043-x · Cited by 5
Non-linear Relationship Between Plasma Amyloid-β 40 Level and Cognitive Decline in a Cognitively Normal Population
Gao, F., Shang, S., Chen, C., Dang, L., Gao, L., Wei, S., Wang, J., Huo, K., Deng, M., Wang, J., et al. (2020) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2020.557005 · Cited by 5
Effect of continuous theta burst stimulation on the glymphatic system, brain network and cognitive function in patients with cerebral small vessel disease
Dai, P., Yu, H., Wang, Z.-X., Liu, S.-H., Liu, C., & Xu, G. (2025) · Frontiers in Human Neuroscience · doi:10.3389/fnhum.2024.1509483 · Cited by 4
Symptomatic Clusters Related to Amyloid Positivity in Cognitively Unimpaired Individuals
Sannemann, L., for the DELCODE Study Group, Bartels, C., Brosseron, F., Büerger, K., Fließbach, K., Freiesleben, S. D., Frommann, I., Glanz, W., Heneka, M. T., et al. (2024) · Journal of Alzheimer s Disease · doi:10.3233/jad-231335 · Cited by 6
Cognitive Performance and Cerebrospinal Fluid Markers in Preclinical Alzheimer’s Disease: Results from the Gothenburg H70 Birth Cohort Studies
Rådestig, M. A., Skoog, J., Zetterberg, H., Kern, J., Zettergren, A., Sacuiu, S. F., Wærn, M., Wetterberg, H., Blennow, K., Skoog, I. G., et al. (2020) · Journal of Alzheimer s Disease · doi:10.3233/jad-200751 · Cited by 5
NEURONORMA Cognitive Battery Associations with Cerebrospinal Fluid Amyloid-β and Tau Levels in the Continuum of Alzheimer’s Disease
García‐Escobar, G., Puig‐Pijoan, A., Puente, V., Fernández‐Lebrero, A., Manero, R. M., Navalpotro‐Gómez, I., Suárez‐Calvet, M., Grau‐Rivera, O., Contador, J., Cascales‐Lahoz, D., et al. (2023) · Journal of Alzheimer s Disease · doi:10.3233/jad-220930 · Cited by 4
Determinants of Cognitive Trajectories in Normal Aging: A Longitudinal PET-MRI Study in a Community-based Cohort
Herrmann, F. R., Montandon, M., Garibotto, V., Rodriguez, C. K., Haller, S., & Giannakopoulos, P. (2021) · Current Alzheimer Research · doi:10.2174/1567205018666210930111806 · Cited by 5
Mid-Adulthood Cognitive Training Improves Performance in a Spatial Task but Does Not Ameliorate Hippocampal Pathology in a Mouse Model of Alzheimer’s Disease
Williams, E., Mutlu-Smith, M., Alex, A., Chin, X. W., Spires‐Jones, T. L., & Wang, S. (2023) · Journal of Alzheimer s Disease · doi:10.3233/jad-221185 · Cited by 5
A robust harmonization approach for cognitive data from multiple aging and dementia cohorts
Giorgio, J., Tanna, A., Malpetti, M., White, S. R., Wang, J., Baker, S. L., Landau, S. M., Tanaka, T., Chen, C., Rowe, J. B., et al. (2023) · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring · doi:10.1002/dad2.12453 · Cited by 4
Cerebrospinal fluid amyloid levels are associated with delayed memory retention in cognitively normal biomarker-negative older adults
Yeung, L., Hale, C., Last, B. S., Andrews, H., Sloan, R. P., Honig, L. S., Small, S. A., & Brickman, A. M. (2019) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2019.08.010 · Cited by 4
Using Pittsburgh Compound B For Pet Imaging Across the Alzheimer’s Disease Spectrum
Cohen, A. D. (2016) · Technology & Innovation · doi:10.21300/18.1.2016.51 · Cited by 4
Biomarkers of Alzheimer’s disease
Bos (2018) · Research Publications (Maastricht University) · doi:10.26481/dis.20181012ib · Cited by 4
Neuronal aging potentiates beta-amyloid generation via amyloid precursor protein endocytosisPreprint
Burrinha, T., Gomes, R. A., Terrasso, A. P., & Almeida, C. G. (2019) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/616540 · Cited by 4
Commentary on Composite cognitive and functional measures for early stage Alzheimer's disease trials
Rentz, D. M., & Papp, K. V. (2020) · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring · doi:10.1002/dad2.12012 · Cited by 4
Integrating individualized connectome with amyloid pathology improves predictive modeling of future cognitive decline
He, H., Razlighi, Q. R., Gazes, Y., Habeck, C. G., Stern, Y., Initiative, A. D. N., Weiner, M. W., Aisen, P. S. S., Petersen, R. C., Jack, C. R., et al. (2025) · Communications Medicine · doi:10.1038/s43856-025-01170-5 · Cited by 5
Self-citation
Prediction of Subtle Cognitive Decline in Normal Aging: Added Value of Quantitative MRI and PET Imaging
Giannakopoulos, P., Montandon, M., Rodriguez, C. K., Haller, S., Garibotto, V., & Herrmann, F. R. (2021) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2021.664224 · Cited by 3
Performance on complex memory tests is associated with β‐amyloid in individuals at risk of developing Alzheimer's disease
Kjeldsen, P. L., Damholdt, M. F., Madsen, L. S., Nissen, P. H., Aanerud, J., Parbo, P., Ismail, R., Kaasing, M., Eskildsen, S. F., Østergaard, L., et al. (2023) · Journal of Neuropsychology · doi:10.1111/jnp.12332 · Cited by 4
A Data-Driven Cognitive Composite Sensitive to Amyloid-β for Preclinical Alzheimer’s Disease
Liu, S., Maruff, P. T., Fedyashov, V., Masters, C. L., & Goudey, B. (2024) · Journal of Alzheimer s Disease · doi:10.3233/jad-231319 · Cited by 4
Improvement of cognitive performance by a nutraceutical formulation: Underlying mechanisms revealed by laboratory studies
Shea, T. B. (2021) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2021.07.039 · Cited by 3
Heterogeneity of cerebral atrophic rate in mild cognitive impairment and its interactive association with proteins related to microglia activity on longitudinal cognitive changes
Tang, J., Cao, Z., Lei, M., Yu, Q., Mai, Y., Xu, J., Liao, W., Ruan, Y., Shi, L., Yang, L., et al. (2024) · Archives of Gerontology and Geriatrics · doi:10.1016/j.archger.2024.105582 · Cited by 2
Clinically meaningful changes in cognitive and functional outcomes in a population‐based study of cognitive aging
Aakre, J. A., Castillo, A. M., Graff‐Radford, J., Vemuri, P., Machulda, M. M., Jack, C. R., Knopman, D. S., Petersen, R. C., & Vassilaki, M. E. (2025) · Alzheimer s & Dementia Translational Research & Clinical Interventions · doi:10.1002/trc2.70160 · Cited by 2
Self-citation
Identification of Hasegawa Dementia Scale‐Revised Cutoff Scores Associated With Mini‐Mental State Examination Thresholds for Anti‐Amyloid β Therapies in Patients With Amnesia
Yamakami, K., Matsubara, T., Fujita, K., Nakamura, K., Kihara, N., Sogawa, K., Nakao, R., Hanada, K., Yamamoto, Y., Haji, S., et al. (2025) · Psychogeriatrics · doi:10.1111/psyg.70107 · Cited by 2
Amyloid Deposition Is Greater in Cerebral Gyri than in Cerebral Sulci with Worsening Clinical Diagnosis Across the Alzheimer’s Disease Spectrum
Walden, L. M., Initiative, A. D. N., Hu, S., Madabhushi, A., & Prescott, J. W. (2021) · Journal of Alzheimer s Disease · doi:10.3233/jad-210308 · Cited by 2
Higher Amyloid and Tau Burden Is Associated With Faster Decline on a Digital Cognitive Test
Fu, J. F., Robinson, T. L., Alonso, M. R., Francis-Malavé, A. M., Jutten, R. J., Properzi, M. J., Healy, B. C., Thompson, J. C., Montenegro, G. D. C., Thibault, E. G., et al. (2025) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.70233 · Cited by 2
Neural correlates of exceptional memory ability in SuperAgers: A multimodal approach using FDG-PET, PIB-PET, and MRIPreprint
Borelli, W. V., Leal‐Conceição, E., Andrade, M. A., Esper, N. B., Feltes, P. K., Soder, R. B., Matushita, C. S., Hartmann, L. M., Radaelli, G., Schilling, L. P., et al. (2019) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/666438 · Cited by 2
Amyloid Beta Hypothesis: Attention to β- and γ-Secretase Modulators
Korábečný, J., Špilovská, K., Soukup, O., Doležal, R., & Kuča, K. (2018) · InTech eBooks · doi:10.5772/intechopen.75629 · Cited by 1
The Pathology, Alzheimer’s and Related Dementias Study (PARDoS): Design and Characteristics of the First 4,700+ Brazilian Participants
Farfel, J. M., Capuano, A. W., Nag, S., Sampaio, M. C. M., Gibbons, J., Wilson, R. S., & Bennett, D. A. (2025) · Neuroepidemiology · doi:10.1159/000547564 · Cited by 1
The association between amyloid-beta deposition on dual-task gait performance is partially moderated by cognitive functions in healthy older adults
Droby, A., Kurkure, M., Maidan, I., Habeck, C. G., Hausdorff, J. M., Stern, Y., & Mirelman, A. (2025) · Scientific Reports · doi:10.1038/s41598-025-28077-4 · Cited by 1
The effect of Apolipoprotein E4 on cognitive function in Parkinson’s disease: A structural MRI study in the PPMI cohort
Rosal, A. E., Torres‐Carmona, E., Martin, S. L., Boileau, I., Graff‐Guerrero, A., & Strafella, A. P. (2026) · PLoS ONE · doi:10.1371/journal.pone.0341240 · Cited by 1
Morpho-Functional Characterization and miRNA Profiling of the Retina in the 5xFAD Murine Model of Alzheimer's Disease
Guidotti, L., Lucchesi, M., Daghini, E., Amato, R., Neri, G., Corsi, F., Marracci, S., Gargini, C., Borello, U., Cammalleri, M., et al. (2026) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.67.2.31 · Cited by 1
Divergent patterns of cognitive decline in preclinical Alzheimer's disease: Implications for secondary prevention trials
Li, R., Langford, O., Insel, P. S., Sperling, R. A., Raman, R., Aisen, P. S. S., & Donohue, M. (2026) · Alzheimer s & Dementia · doi:10.1002/alz.71366 · Cited by 1
Neuroimaging Biomarkers in Alzheimer’s Disease and Related Disorders
Masdeu, J. C., & Pascual, B. (2023) · Springer eBooks · doi:10.1007/978-3-031-43356-6_11 · Cited by 1
Cognitive Aging and the Transition to Early Alzheimer’s Disease
Mormino, E. C., & Jagust, W. J. (2024) · Oxford University Press eBooks · doi:10.1093/oxfordhb/9780190917982.013.59 · Cited by 1
MRI-Based Medial Temporal Atrophy May Reflect Amyloid PET Positivity in Cognitively Normal Individuals: A Preliminary Study
Arai, H. (2025) · Cureus · doi:10.7759/cureus.96751 · Cited by 1
Impact of the New Conceptual Framework of Alzheimer’s Disease in Imaging Studies
Dubois, B., Villain, N., Jacova, C., & Uspenskaya, O. (2020) · Springer eBooks · doi:10.1007/978-3-030-53168-3_13 · Cited by 1
Detecting Alzheimer Disease Clinically
Petersen, R. C. (2022) · Neurology · doi:10.1212/wnl.0000000000200172 · Cited by 1
Self-citation
Sex, menopause, and Alzheimer’s risk: a 31P-MR spectroscopy study of brain mitochondrial function in association with 11C-PiB PET amyloid-beta loadPreprint
Jett, S., Dyke, J. P., Andy, C., Schelbaum, E., Jang, G., Boneu, C., Pahlajani, S. S., Díaz, I., Brinton, R. D., & Mosconi, L. (2022) · Research Square · doi:10.21203/rs.3.rs-1723651/v1 · Cited by 1
The Path of Alzheimer’s disease
Jansen, W. J. (2016) · Research Publications (Maastricht University) · doi:10.26481/dis.20161125wj
Modifiable risk factors moderate the relationship between beta-amyloid and cognition in midlifePreprint
Clark, L. R., Koscik, R. L., Allison, S. L., Berman, S. E., Carlsson, C. M., Norton, D., Bendlin, B. B., Asthana, S., Betthauser, T. J., Christian, B. T., et al. (2017) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/229062
PET-RM MULTITRAZADOR EN EL ESTUDIO DE LA ENFERMEDAD DE ALZHEIMER
Suárez, A. M., Rodríguez, M. R., de la Peña, M. J., Echávarri, D. E., Cabero, S. F., & de Vega, V. M. (2018) · Seram
Cerebrospinal fluid biomarkers and cognition in older adults
Rådestig, M. A. (2021)
Error in Term Definition
(2016) · JAMA Neurology · doi:10.1001/jamaneurol.2016.0070
Affiliation Error in Group Information Listing
Brouwer, P. A., van der Lugt, A., Emmer, B. J., Majoie, C. B. L. M., Beenen, L. F. M., Sprengers, M. E. S., van den Berg, R., & Berkhemer, O. A. (2016) · JAMA Neurology · doi:10.1001/jamaneurol.2016.0104
Visual Memory and Spatial Navigation as Preclinical Indicators of Alzheimer's DiseasePreprint
Nevers, J. I. (2023) · Research Square · doi:10.21203/rs.3.rs-3253822/v1
Performance change while learning novel cognitive tasks as a potential identifier of preclinical Alzheimer's disease
Hetrick, L. M., Chen, H., Levin, I., Lockhart, S. N., Miller, M. E., Laurienti, P. J., Kritchevsky, S. B., Hugenschmidt, C. E., & Zukowski, L. A. (2025) · Journal of Alzheimer s Disease Reports · doi:10.1177/25424823251356597
Divergent patterns of cognitive decline in preclinical Alzheimer’s disease: implications for secondary prevention trialsPreprint
Li, R., Langford, O., Insel, P. S., Sperling, R. A., Raman, R., Aisen, P. S. S., & Donohue, M. (2025) · medRxiv · doi:10.64898/2025.12.15.25342305
Additional file 1 of NREM sleep as a novel protective cognitive reserve factor in the face of Alzheimer's disease pathology
Zavecz, Z., Shah, V. D., Murillo, O. G., Vallat, R., Mander, B. A., Winer, J. R., Jagust, W. J., & Walker, M. P. (2024) · Figshare · doi:10.6084/m9.figshare.26584560
Additional file 1 of Pathological correlates of impaired self-awareness of memory function in Alzheimer’s disease
Gagliardi, G. P., Kuppe, M. K., Lois, C., Hanseeuw, B. J., & Vannini, P. (2021) · Figshare · doi:10.6084/m9.figshare.14850632
Additional file 1 of No evidence for amyloid pathology as a key mediator of neurodegeneration post-stroke - a seven-year follow-up study
Hagberg, G., Ihle-Hansen, H., Fure, B., Thommessen, B., Ihle‐Hansen, H., Øksengård, A. R., Beyer, M. K., Wyller, T. B., Müller, E. G., Pendlebury, S. T., et al. (2020) · Figshare · doi:10.6084/m9.figshare.12276821
Age-related alterations in plasma biomarkers of relevance to Alzheimer's disease are attenuated in KLOTHO KL-VS heterozygotes
Driscoll, I. F., Wilson, R. E., Johnson, S. C., Asthana, S., Gallagher, C. L., Hermann, B. P., Sager, M. A., Carlsson, C. M., Blennow, K., Zetterberg, H., et al. (2026) · Journal of Alzheimer s Disease · doi:10.1177/13872877261422411
Association between amyloid-β deposition and cognitive function in cognitively normal adults: a multilevel meta-analysis
Huang, Y., Gong, Q., Zhong, Z., & Guo, Q.-H. (2026) · Alzheimer s Research & Therapy · doi:10.1186/s13195-026-02061-0
Higher amyloid deposition and lower white matter volume in cognitively healthy seniors exceeding French alcohol recommendations
Soussi, C., Gonneaud, J., Cabé, N., Lanièpce, A., Marchant, N. L., Collette, F., de Florès, R., Foyard, E., Landeau, B., Mézenge, F., et al. (2026) · EBioMedicine · doi:10.1016/j.ebiom.2026.106376
Evaluating the 8‐Year Association Between Cognition and Beta Amyloid in the Dallas Lifespan Brain Study Cohort
David, J., Torres, I. (. T., Smith, E. T., Pongpipat, E. E., & Park, D. C. (2026) · Brain and Behavior · doi:10.1002/brb3.71684

Authors: Petersen, R. C., Wiste, H. J., Weigand, S. D., Rocca, W. A., Roberts, R. O., Mielke, M. M., Lowe, V. J., Knopman, D. S., Pankratz, V. S., Machulda, M. M., Geda, Y. E., & Jack, C. R.
Affiliations: Mayo Clinic (US)
ORCID: Petersen, Ronald C.
Wiste, Heather J.
Weigand, Stephen D.
Rocca, Walter A.
Mielke, Michelle M.
Lowe, Val J.
Knopman, David S.
Pankratz, Vernon S.
Machulda, Mary M.
Geda, Yonas E.
Jack, Clifford R.
Venue: JAMA Neurology
Publisher: American Medical Association (AMA)
Published: 2016-01-01
Volume: 73
Issue: 1
Pages: 85
ISSN: 2168-6149 (ISSN-L)
DOI: 10.1001/jamaneurol.2015.3098
PMC: PMC4710552
OpenAlex: W2174862691
Cited by: 196
References: 36
Citations by year: 2026: 7 · 2025: 13 · 2024: 13 · 2023: 14 · 2022: 12 · 2021: 25 · 2020: 21 · 2019: 27 · 2018: 26 · 2017: 22 · 2016: 16
FWCI: 17.33
Type: journal article
Language: en
Open access: green
www.ncbi.nlm.nih.gov
Locations: JAMA Neurology (publishedVersion)
PubMed (publishedVersion)
Europe PMC (PubMed Central) (acceptedVersion)
PubMed Central (acceptedVersion)
Funders: National Institutes of Health (5u01ag024904-10)
National Institute on Aging (U01-AG-024904, R01AG034676, R01AG029550, P50AG044170, R01AG043392, R01AG040042, R01AG041581, U01AG006786, R01AG011378, R01AG032306, R01AG032990, R01AG037551, R01AG041851, P50AG016574)
National Heart, Lung, and Blood Institute (U01HL096917)
Topics: Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
Health Sciences › Medicine › Oncology › Cancer-related cognitive impairment studies
Keywords: amyloid accumulation, Alzheimer's disease, cognitively normal older adults, cognitive decline, mild cognitive impairment, hippocampal atrophy, ventriculomegaly, FDG-PET hypometabolism, Pittsburgh compound B PET, APOE ε4, amyloid biomarkers, Mayo Clinic Study of Aging, longitudinal cognitive change
MeSH terms: Aged, Aged, 80 and over, Brain, Cognition, Female, Follow-Up Studies, Humans, Longitudinal Studies, Male, Population Surveillance, Residence Characteristics, Cohort Studies, Biomarkers, Amyloid beta-Peptides, Positron-Emission Tomography, Cognitive Dysfunction

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Association of Elevated Amyloid Levels With Cognition and Biomarkers in Cognitively Normal People From the Community

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks